Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Carbohydrate doai
Reexamination Certificate
2005-06-21
2005-06-21
Wilson, James O. (Department: 1623)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Carbohydrate doai
C514S451000, C514S453000, C514S454000, C514S012200
Reexamination Certificate
active
06908902
ABSTRACT:
Co-therapy for the treatment of neurological dysfunctions comprising administration of one or more fructopyranose sulfamates and erythropoietin.
REFERENCES:
patent: 4513006 (1985-04-01), Maryanoff et al.
patent: 4703008 (1987-10-01), Lin
patent: 5242942 (1993-09-01), Costanzo et al.
patent: 5354934 (1994-10-01), Pitt et al.
patent: 5384327 (1995-01-01), Costanzo et al.
patent: 5571787 (1996-11-01), O'Brien
patent: 5643575 (1997-07-01), Martinez et al.
patent: 5688679 (1997-11-01), Powell
patent: 5696080 (1997-12-01), O'Brien et al.
patent: 5700909 (1997-12-01), O'Brien
patent: 5714459 (1998-02-01), O'Brien
patent: 5753694 (1998-05-01), Shank
patent: 5767078 (1998-06-01), Johnson et al.
patent: 5773569 (1998-06-01), Wrighton et al.
patent: 6001800 (1999-12-01), Mehta et al.
patent: 640619 (1995-03-01), None
patent: WO 94/12650 (1994-06-01), None
patent: WO 95/03034 (1995-02-01), None
patent: WO 96/40772 (1996-12-01), None
patent: WO 98/00124 (1998-01-01), None
patent: WO 98/05363 (1998-02-01), None
patent: WO 99/05268 (1999-02-01), None
patent: WO 99/11781 (1999-03-01), None
patent: WO 99/21966 (1999-05-01), None
patent: WO 99/38890 (1999-08-01), None
patent: WO 99/66054 (1999-12-01), None
patent: WO 00/61138 (2000-10-01), None
patent: WO 00/61138 (2000-10-01), None
patent: WO 00/61164 (2000-10-01), None
Temple et al., Recombinant erythropoietin improves cognitive function in patients maintained on chronic ambulatory peritoneal dialysis, Nephrol Dial Transplant (1995) 10:1733-1738.
Sachdeo, Rajesh C., Topiramate: Clinical Profile in Epilepsy, Clin Pharmacokinet, May 1998, 34(5):335-346.
NINDS Traumatic Brain Injury Information Page: http://www.ninds.nih.gov/health_and_medical /disorders/tbi_doc.htm; Jul. 1, 2001.
Maryanoff et al., Structure-Activity Studies on Anticonvulsant Sugar Sulfamates Related to Topiramate. Enhanced Potency with Cyclic Sulfamate Derivatives, J. Med. Chem., 1998, vol. 41, pp. 1315-1343.
NINDS Alzheimer's Disease Information Page: http://www.ninds.nih.gov/health_and_medical/disorders/alzheimersdisease_doc.htm; Sep. 10, 2003.
NINDS Epliepsy Information Page: http://www.ninds.nih.gov/health_and_medical/disorders/epilepsy.htm; Jul. 1, 2001.
NINDS Multiple Sclerosis Information Page: http://www.ninds.nih.gov/health_and_medical/disorders/epilepsy.htm; Jul. 1, 2001.
Alafaci et al., “Effect of Recombinant Human Erythropoietin on Cerebral Ischemia Following Experimental Subarachnoid Hemorrhage”,Eur. J. Pharmacol.(2000) 406(2):219-225.
Aldenkamp et al., “A Multicenter, Randomized Clinical Study to Evaluate the Effect on Cognitive Function of Topiramate Compared with Valproate as Add-On Therapy to Carbamazepine in Patients with Partial-Onset Seizures”,Epilepsia(2000) 41(9):1167-1178.
William M. Armstead, “Age-Dependent Cerebral Hemodynamic Effects of Traumatic Brain Injury in Newborn and Juvenile Pigs”,Microcirculation(2000) 7(4):225-235.
D. M. Basso, “Neuroanatomical Substrates of Functional Recovery after Experimental Spinal Cord Injury: Implications of Basic Science Research for Human Spinal Cord Injury”,Phys. Ther.(2000) 80(8):808-817.
Bernaudin et al., “A Potential Role for Erythropoietin in Focal Permanent Cerebral Ischemia in Mice”,J. Cereb. Blood Flow Metab.(1999) 19(6):643-651.
Robert F. Brady, “Cyclic Acetals of Ketoses, Part III: Re-Investigation of the Synthesis of the IsomericDI-O-isopropylidene-β-D-Fructopyranoses”,Carbohydrate Res.(1970) 15(1):35-40.
Brines et al., “Erythropoietin Crosses the Blood-Brain Barrier to Protect Against Experimental Brain Injury”,P. N. A. S. U S A(2000) 97(19):10526-10531.
Leslie A. Burton and Cynthia Harden, “Effect of Topiramate on Attention”,Epilepsy Res.(1997) 27(1):29-32.
Campana et al., “Identification of a Neurotrophic Sequence of Erythropoietin”,Inter. J. Mol. Med.(1998) 1(1):235-241.
Di Giulio et al., “Glycosaminoglycans Co-Administration Enhance Insulin-Like Growth Factor-I Neuroprotective and Neuroregenerative Activity in Traumatic and Genetic Models of Motor Neuron Disease: A Review”,Int. J. Dev. Neurosci.(2000) 18(4-5):339-346.
Faught et al., “Topiramite Dose-Ranging Trial in Refractory Partial Epilepsy”,Epilepsia(1995) 36(S4): p. 33.
Tracy A. Glauser, “Video Atlas of Epileptic Seizures: Classical Examples”,Epilepsia(1999) 40(S5):S71-80. vol. 40(5) pp. 664-5.
Greco et al., “The Search for Synergy: A Critical Review from a Response Surface Perspective”,Pharmacol. Rev.(1995) 47(2):331-385.
Byung H. Han and David M. Holtzman, “BDNF Protects the Neonatal Brain from Hypoxic-Ischemic Injury In Vivo via the ERK Pathway”,J. Neurosci.(2000) 20(15):5775-5781.
Mir Hedayatullah and Alain Guy, “Synthesis and Reduction of Aryl Azidosulfates (Synthese et Reduction d'Azidosulfates d'Aryle)”,Tetrahedron Lett.(1975), 16(29):2455-2458.
Herbert O. House, “Metal Hydride Reductions and Related Reductions”,Modern Synthetic Reactions(Organic Chemistry Monograph Series), 2ndEd. (Benjamin-Cummings Publishing Co., Menlo Park, CA 1972) pp. 45-144.
Juul et al., “Immunohistochemical Localization of Erythropoietin and its Receptors in the Developing Human Brain”,Pediatr. Dev. Pathol.(1999) 2(2):148-158.
Juul et al., Erythropoietin and Erythropoietin Receptor in the Developing Human Central Nervous System,Pediatr. Res.(1998) 43(1):43(1):40-49.
Juul et al., “Erythropoietin in the Cerebrospinal Fluid of Neonates who Sustained CNS Injury”,Pediatr. Res.(1999) 46(5):543-547.
L. Kambova, “Recombination Erythropoietin Improves Cognitive Function in Chronic Haemodialysis Patients”,Nephrol. Dial. Transplant.(1998) 13(1):229.
Koshimura et al., “Effects of Erythropoietin on Neuronal Activity”,J. Neurochem.(1999) 72(6):2565-2572.
Sanford B. Krantz, “Erythropoietin”,Blood(1991) 77(3): 419-434.
Gerald L. Larson and Antonio Hernandez, “Reaction of Trimethylsilyl Enol Ethers with Diols”,J. Org. Chem.(1973) 38(22):3935-3936.
H. L. Laurer and T. K. McIntosh, “Experimental Models of Brain Trauma”,Curr. Opin. Neurol.(1999) 12(6):715-721.
Lee et al., “Protective Effect of Topiramate Against Hippocampal Neuronal Damage after Global Ischemia in the Gerbils”,Neuroscience Letters(2000) 281(2-3):183-186.
Maryanoff et al., “Anticonvulsant O-Alkyl Sulfamates: 2,3:4,5-Bis-O-(1-Methylethylidene)-Beta-D-Fructopyranose Sulfamate and Related Compounds”,J. Medicinal Chemistry(1987) 30(5):880-887.
Maryanoff et al., “Anticonvulsant Sugar Sulfamates: Potent Cyclic Sulfate and Cyclic Sulfite Analogues of Topiramate”,Bioorg. Med. Chem. Lett.(1993) 3(12):2653-2656.
Maryanoff et al., “Structure—Activity Studies on Anticonvulsant Sugar Sulfamates Related to Topiramate: Enhanced Potency with Cyclic Sulfate Derivatives”,J. Med. Chem.(1998) 41(8):1315-1343.
M. Mason-Garcia and B. S. Beckman, “Signal Transduction in Erythropiesis”,Faseb Journal(1991) 5(14): 2958-2964.
Mattson et al., “Calcium, Free Radicals and Excitotoxic Neuronal Death in Primary Cell Culture”,Methods Cell Biol.(1994) 46:187-216.
Italo Mocchetti and Jean R. Wrathall, “Neurotropic Factors In Central Nervous System Trauma”,J. Neurotrauma(1995) 12(5):853-870.
Morishita et al., “Erythropoietin Receptor is Expressed in Rat Hippocampal and Cerebral Cortical Neurons, and Erythropoietin Prevent In Vitro Glutamate-Induced Neuronal Death”,Neuroscience(1997) 76(1):105-116.
Nakamura et al., “Inhibition by Topiramate of Seizures in Spontaneously Epileptic Rats and DBA/2 Mice”,Eur. J. Pharmacol.(1994) 254(1-2):83-89.
Newey et al., “Alternative Splicing of Dystrobrevin Regulates the Stoichiometry of Syntrophin Binding to the Dystrophin Protein Complex”,Curr. Biol.(2000) 10(20):1295-1298.
A. R. Nissenson, “Eptoein And Cognitive Function”,Am. J. Kidney Di
Plata-Salaman Carlos
Smith-Swintosky Virginia
McIntosh III Traviss C.
Ortho-McNeil Pharmaceutical , Inc.
Wilson James O.
Woodcock & Washburn LLP
LandOfFree
Treatment of neurological dysfunction comprising... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Treatment of neurological dysfunction comprising..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Treatment of neurological dysfunction comprising... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3504788